Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells.

Journal article

Dendritic cell (DC)-based immunization represents a promising approach for the immunotherapy of cancer. The optimal conditions required to prepare DCs remain to be defined. Monocytes incubated in the presence of interferon (IFN)-beta and interleukin (IL)-3 give rise to a distinct type of DCs (IFN-beta/IL-3 DCs) that are particularly efficient at eliciting IFN-gamma and IL-5 production by allogeneic helper T cells. We assessed the capacity of this new type of DCs to prime antigen-specific naive CD8(+) T cells and compared them to the conventional DCs differentiated in the presence of granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-4 (GM-CSF/IL-4 DCs). We demonstrate that IFN-beta/IL-3 DCs matured by TLR3 or CD40 ligation efficiently prime Melan-A(26-35)-specific CD8(+) T cells in vitro, at a similar level as GM-CSF/IL-4 DCs. Activated antigen-specific CD8(+) T cells produced IFN-gamma and displayed potent cytotoxic activity against peptide-pulsed target cells. Expansion of CD8(+) T cell numbers was generally higher following priming with CD40-L than with polyinosinic-polycytidylic acid (poly I:C) matured DCs. Cytolytic activity was induced by both maturing agents. These data indicate that IFN-beta/IL-3 DCs represent a promising cell population for the immunotherapy of cancer.

Authors: Renneson, J; Salio, M; Mazouz, N; Goldman, M; Marchant, A

• Publication status: Published
• Journal: Clinical and experimental immunology
• Volume: 139
• Issue: 3
• Pages: 468-475
• Publication date: 2005-03-01
• DOI: 10.1111/j.1365-2249.2005.02700.x
• EISSN: 1365-2249
• ISSN: 0009-9104
• Language: English
• Keywords: CD40 Ligand; Cancer Vaccines; T-Lymphocytes, Cytotoxic; Cell Line, Tumor; Cell Differentiation; Interferon-gamma; Flow Cytometry; Lymphocyte Activation; Dendritic Cells; Humans; Lymphoma; Interleukin-5; CD8-Positive T-Lymphocytes; Interleukin-3; Interferon-beta